Tratamiento multimodal de carcinoma adrenocortical metastásico: caso clínico y propuesta de estrategia integral en Colombia

Multimodal Treatment of Metastatic Adrenal Cortical Carcinoma: Clinical Case and Proposed Comprehensive Strategy in Colombia

Publicado 2024-12-05

Abrir | Descargar
PDF FLIP
Número
Vol. 11 Núm. 2 (2024): Julio - Diciembre
Sección
Casos clínicos
Cómo citar
Tratamiento multimodal de carcinoma adrenocortical metastásico: caso clínico y propuesta de estrategia integral en Colombia.
Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2024 Dec. 21];11(2):93-102. Disponible en: https://doi.org/10.51643/22562915.699
DOI

https://doi.org/10.51643/22562915.699
Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Lucy Maritza Pérez Lugo
Fundación Valle del Lili , Universidad ICESI, Cali, Colombia image/svg+xml
    https://orcid.org/0009-0002-8440-0361
    Álvaro Enrique Osorio Franco
    Fundación Valle del Lili , Cali, Colombia. image/svg+xml
      Mostrar biografía de los autores

      Lucy Maritza Pérez Lugo,

      Médica internista, Fellow de Hematología y Oncología. Fundación Valle de Lili y Universidad ICESI.

      Álvaro Enrique Osorio Franco,

      Médico internista, Hematólogo y Oncólogo. Fundación Valle de Lili.

      La frecuencia de los tumores adrenales es alta, llegando a afectar entre un 3 a 10 % de la población. Por el contrario, el carcinoma adrenocortical es una enfermedad rara que tiene una incidencia estimada en 0.7 casos por millón por año. En la mayoría de los pacientes con carcinoma adrenocortical se logra demostrar sobreproducción hormonal, siendo el síndrome de Cushing el cuadro clínico más frecuentemente asociado. Existe poca evidencia acerca del tratamiento óptimo de esta entidad. Caso clínico: presentamos el caso de una mujer de 60 años con un síndrome de Cushing secundario a un carcinoma adrenocortical con compromiso metastásico a hígado, tratada de manera multimodal con cirugía, radioterapia y manejo sistémico con mitotane. Conclusión: este caso contribuye significativamente al modelo actual de atención en Colombia para este tipo de neoplasia rara, y plantea una estrategia integral de tratamiento de acuerdo con elementos pronósticos identificados en el estudio histopatológico y con los últimos avances a nivel mundial.

      Visitas del artículo 21 | Visitas PDF 17

      1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress? World J Surg [Internet]. 2006;30(5):1658. Disponible en: https://doi.org/10.1007/s00268-005-0329-x
      2. Passman JE, Amjad W, Soegaard Ballester JM, Ginzberg SP, Wachtel H. Defining Optimal Management of Non-metastatic Adrenocortical Carcinoma. Ann Surg Oncol [Internet]. 2024;31(2):1097-1107. Disponible en: https://doi.org/10.1245/s10434-023-14533-w
      3. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer [Internet]. 1993;72(11):3145-3155. Disponible en: https://doi.org/10.1002/1097-0142(19931201)72:11<3145::aid-cncr2820721105>3.0.co;2-n
      4. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol [Internet]. 2013;169(6):891-899. Disponible en: https://doi.org/10.1530/EJE-13-0519
      5. Alexander K, Katherine M, Daniel C, Yu-Ning W, G UR. Effects of Increased Cross-Sectional Imaging on the Diagnosis and Prognosis of Adrenocortical Carcinoma: Analysis of the National Cancer Database. Journal of Urology [Internet]. 2011;186(3):805-810. Disponible en: https://doi.org/10.1016/j.juro.2011.04.072
      6. Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. British Journal of Surgery [Internet]. 2015;102(4):291-306. Disponible en: https://doi.org/10.1002/bjs.9743
      7. Libé R, Huillard O. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun [Internet]. 2023;37:100759. Disponible en: https://doi.org/https://doi.org/10.1016/j.ctarc.2023.100759
      8. Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology [Internet]. 2015;26(10):2119-2125. Disponible en: https://doi.org/10.1093/annonc/mdv329
      9. Ng L, Libertino J. Adrenocortical Carcinoma: Diagnosis, Evaluation and Treatment. J Urol [Internet]. 2003;169:5-11. Disponible en: https://doi.org/10.1097/01.ju.0000030148.59051.35
      10. Libé R, Huillard O. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun [Internet]. 2023;37:100759. Disponible en: https://doi.org/10.1016/j.ctarc.2023.100759
      11. Schteingart DE. Adjuvant Mitotane Therapy of Adrenal Cancer-Use and Controversy. New England Journal of Medicine [Internet]. 2007;356(23):2415-2418. Disponible en: https://doi.org/10.1056/NEJMe078087
      12. Koch CA, Pacak K, Chrousos GP. The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. J Clin Endocrinol Metab [Internet]. 2002;87(12):5367-5384. Disponible en: https://doi.org/10.1210/jc.2002-021069
      13. Zheng S, Cherniack AD, Dewal N, et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell [Internet]. 2016;29(5):723-736. Disponible en: https://doi.org/10.1016/j.ccell.2016.04.002
      14. Juhlin CC, Goh G, Healy JM, et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism [Internet]. 2015;100(3):E493-E502. Disponible en: https://doi.org/10.1210/JC.2014-3282
      15. Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet [Internet]. 2014;46(6):607-612. Disponible en: https://doi.org/10.1038/ng.2953
      16. Abiven G, Coste J, Groussin L, et al. Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients. J Clin Endocrinol Metab [Internet]. 2006;91(7):2650-2655. Disponible en: https://doi.org/10.1210/jc.2005-2730
      17. Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol [Internet]. 2018;179(4):G1-G46. Disponible en: https://doi.org/10.1530/EJE-18-0608
      18. McCarthy CJ, McDermott S, Blake MA. Adrenal Imaging: Magnetic Resonance Imaging and Computed Tomography. Front Horm Res [Internet]. 2016;45:55-69. Disponible en: https://doi.org/10.1159/000442313
      19. Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2020;31(11):1476-1490. Disponible en: https://doi.org/10.1016/j.annonc.2020.08.2099
      20. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer [Internet]. 2009;115(2):243-250. Disponible en: https://doi.org/https://doi.org/10.1002/cncr.24030
      21. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer. [Internet] 2010;46(4):713-719. Disponible en: https://doi.org/10.1016/j.ejca.2009.12.007
      22. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization. Journal of Clinical Oncology 2002;20(4):941-950. Disponible en: https://doi.org/10.1200/JCO.2002.20.4.941
      23. Vassilopoulou-Sellin R, Schultz P. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer [Internet]. 2001;92:1113-1121. Disponible en: https://doi.org/10.1002/1097-0142(20010901)92:5<1113::aid-cncr1428>3.0.co;2-i
      24. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg [Internet]. 2001;25(7):891-897. Disponible en: https://doi.org/10.1007/s00268-001-0047-y
      25. Schulick RD, Brennan MF. Long-Term Survival After Complete Resection and Repeat Resection in Patients With Adrenocortical Carcinoma. Ann Surg Oncol [Internet]. 1999;6(8):719-726. Disponible en: https://doi.org/10.1007/s10434-999-0719-7
      26. Gaujoux S, Mihai R, Carnaille B, et al. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. British Journal of Surgery [Internet]. 2017;104(4):358-376. Disponible en: https://doi.org/10.1002/bjs.10414
      27. Waszut U, Szyska P, Dworakowska D. Understanding mitotane mode of action. J Physiol Pharmacol. [Internet]. 2017;68:13-26. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28456766/ PMID: 28456766
      28. Terzolo M, Zaggia B, Allasino B, De Francia S. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes [Internet]. 2014;21(3). Disponible en: https://journals.lww.com/co-endocrinology/fulltext/2014/06000/practical_treatment_using_mitotane_for.4.aspx
      29. Terzolo M, Fassnacht M, Perotti P, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol [Internet]. 2023;11(10):720-730. Disponible en: https://doi.org/10.1016/S2213-8587(23)00193-6
      30. Kimpel O, Bedrose S, Megerle F, et al. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer [Internet]. 2021;125(9):1233-1238. Disponible en: https://doi.org/10.1038/s41416-021-01513-8
      31. Else T, Kim AC, Sabolch A, et al. Adrenocortical Carcinoma. Endocr Rev [Internet]. 2014;35(2):282-326. Disponible en: https://doi.org/10.1210/er.2013-1029
      32. Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer [Internet]. 2009;115(13):2816-2823. Disponible en: https://doi.org/10.1002/cncr.24331
      33. Paragliola RM, Corsello A, Locantore P, Papi G, Pontecorvi A, Corsello SM. Medical Approaches in Adrenocortical Carcinoma. Biomedicines [Internet]. 2020;8(12):1-18. Disponible en: https://doi.org/10.3390/BIOMEDICINES8120551
      34. Fassnacht M, Terzolo M, Allolio B, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine [Internet]. 2012;366(23):2189-2197. Disponible en: https://doi.org/10.1056/NEJMoa1200966
      35. Raj N, Zheng Y, Kelly V, et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal of Clinical Oncology [Internet]. 2019;38(1):71-80. Disponible en: https://doi.org/10.1200/JCO.19.01586
      36. Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer [Internet]. 2019;7(1):253. Disponible en: https://doi.org/10.1186/s40425-019-0722-x
      37. Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer [Internet]. 2020;8(1):e000347. Disponible en: https://doi.org/10.1136/jitc-2019-000347
      38. Chukkalore D, MacDougall K, Master V, Bilen MA, Nazha B. Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. Oncologist [Internet]. February 21, 2024:oyae029. Disponible en: https://doi.org/10.1093/oncolo/oyae029

      Información

      Directorios e indexadores
      Perfil de Google Scholar

      Código QR

      Palabras clave

      Más leídos en los últimos 30 días

      Número actual

      Sistema OJS 3.4.0.7 - Metabiblioteca |